This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: I36 (Nonrheumatic tricuspid valve disorders) | Special Copayment Reduction: V192 (heart disease special copayment reduction: 5% copayment for up to 30 days from the registration date) |
| B. Synonyms | Functional tricuspid insufficiency, secondary tricuspid regurgitation, atrial tricuspid regurgitation, Functional tricuspid regurgitation, Secondary TR, Atrial secondary TR |
| C. Adult onset | Can present throughout adulthood but is especially frequent in older patients with atrial fibrillation, left heart failure, or pulmonary hypertension. Atrial secondary tricuspid regurgitation is increasing in women and older adults. |
| 1. History | Changing recognition of tricuspid valve disease and the history of surgical and transcatheter treatment; emergence of FDA-approved transcatheter tricuspid procedures in 2024 |
| 2. Causes | Secondary (functional): annular dilation due to left heart failure, pulmonary hypertension, atrial fibrillation; primary: infective endocarditis, carcinoid, Ebstein anomaly |
| 3. Genetics | MYH7 and NKX2-5 gene mutations associated with Ebstein anomaly; rare reports of familial tricuspid valve disease |
| 4. General epidemiology | Prevalence of moderate or greater tricuspid regurgitation about 0.55%; about 90% of all TR is secondary; rising sharply in older women |
| 5. Pathophysiology | Vicious cycle of right ventricular pressure/volume overload → annular dilation → inadequate leaflet coaptation (tethering) → worsening regurgitation; the atrial mechanism is separate |
| 6. Symptoms | Right heart failure symptoms: lower extremity edema, abdominal distension, ascites, anorexia, jaundice; reduced exercise tolerance, fatigue |
| 7. Signs | Elevated jugular venous pressure, systolic jugular venous regurgitant pulsation, diastolic-systolic murmur, hepatomegaly, ascites, lower extremity edema, pulsatile hepatomegaly |
| 8. Screening | Regular echocardiography in patients with atrial fibrillation, left heart failure, or pulmonary hypertension; prompt evaluation when right heart failure symptoms are reported |
| 9. Diagnosis | Echocardiography (2D/3D, Doppler), quantification of EROA and regurgitant volume, transesophageal echocardiography, cardiac CT and MRI |
| 10. Treatment | Treatment of the underlying disease first; surgical tricuspid valve repair and replacement; transcatheter tricuspid repair (TriClip) and replacement (EVOQUE, 2024 FDA approval) |
| 11. Prognosis | 1-year mortality of severe TR about 36%; poor with concomitant right heart failure; improved quality of life and survival after transcatheter procedures |
| 12. Prevention | Early treatment and prevention of the underlying heart disease (left heart failure, atrial fibrillation, pulmonary hypertension); consider concomitant tricuspid repair during left-sided valve surgery |
| 13. References | Dreyfus GD et al. Secondary tricuspid regurgitation or dilatation: which should be the criterion for surgical repair? … and 9 other papers |
Historically, tricuspid valve disease has been relatively underestimated compared with left-sided valve disease. Until the mid-20th century, tricuspid regurgitation was regarded as a "benign disease," or the prevailing practice was to expect spontaneous improvement after left-sided valve surgery. However, as observational study results accumulated throughout the 1970s–80s showing that tricuspid regurgitation independently increases mortality, the need for active treatment emerged.
In the surgical approach, tricuspid valve repair began to develop in earnest in 1971 when DeVega described suture annuloplasty (DeVega annuloplasty). Subsequently, systematic valve repair using the Carpentier ring was developed, and in the 1980s–90s it was gradually recognized that functional tricuspid regurgitation should be corrected at the same time as left-sided valve surgery. In the 2000s, annular dilation criteria were established through studies by Dreyfus et al., and the concept became established that tricuspid repair should be performed prophylactically during left-sided valve surgery even in the absence of symptoms.
The 21st century has opened the era of transcatheter tricuspid procedures. In February 2024 the US FDA approved the EVOQUE transcatheter tricuspid valve replacement system, and in April 2024 the TriClip transcatheter tricuspid edge-to-edge repair procedure. This opened new horizons for treating tricuspid regurgitation in patients at high surgical risk, and safety and efficacy were validated through clinical trials such as the TRILUMINATE Pivotal study. Recognition of atrial secondary tricuspid regurgitation as an independent phenotype was further systematized in a 2024 European Heart Journal paper.
Nonrheumatic tricuspid valve disorders are broadly divided into primary (organic) and secondary (functional). About 90% of all tricuspid regurgitation is secondary.
The causes of secondary tricuspid regurgitation are broadly divided into two mechanisms. The first is the traditional mechanism (ventricular secondary TR), in which right ventricular pressure/volume overload due to left heart failure, mitral valve disease, pulmonary hypertension, and so on causes annular dilation and leaflet tethering. The second is atrial secondary TR (A-STR), which arises from dilation of the tricuspid annulus due to atrial arrhythmias such as atrial fibrillation or atrial flutter and atrial enlargement. A-STR is observed mainly in older women and in patients with atrial fibrillation or heart failure with preserved ejection fraction.
The main causes of primary tricuspid valve disorders include Ebstein anomaly (downward displacement of the tricuspid leaflets into the right ventricle), infective endocarditis (especially frequent in intravenous drug users), carcinoid syndrome (plaque formation on the right heart valves with stenosis and insufficiency), trauma, fibrosis after radiation therapy, and drug-induced valve changes (fenfluramine/dexfenfluramine, ergotamine derivatives). Secondary damage related to implanted cardiac devices (e.g., leaflet damage by pacemaker leads) is also an important iatrogenic cause.
Genetic factors in nonrheumatic tricuspid valve disorders are mainly related to primary tricuspid malformations. Ebstein anomaly mostly occurs sporadically, but in some familial cases mutations in the MYH7 (beta-myosin heavy chain gene), NKX2-5 (cardiac transcription factor), and GATA4 genes have been reported. Lithium exposure during pregnancy has been reported to be associated with Ebstein anomaly, but recent studies have suggested that the risk may be lower than previously thought.
Tricuspid stenosis is a very rare disease, and nonrheumatic causes include carcinoid syndrome, congenital tricuspid stenosis, or variants of Ebstein anomaly. In carcinoid syndrome, tricuspid valve involvement is due to excessive secretion of serotonin and other vasoactive substances, and the genetic factor itself may be related to SERT gene polymorphisms.
Genetic predisposition to atrial fibrillation or heart failure associated with secondary tricuspid regurgitation also indirectly determines the risk of tricuspid regurgitation, and various related genetic variants (SCN5A, KCNQ1, TTN, etc.) are under study. Overall, secondary tricuspid regurgitation is influenced more by acquired cardiovascular risk factors than by genetics.
Tricuspid regurgitation is a fairly common valve abnormality in the general population; including mild regurgitation, it is found in about 65–85% of adults on Doppler echocardiography. The prevalence of clinically significant moderate or greater tricuspid regurgitation is estimated at about 0.55%. This rate increases markedly with comorbidities such as advanced age, atrial fibrillation, left-sided valve disease, and pulmonary hypertension.
In terms of sex, primary tricuspid valve disease is slightly more common in men, but secondary tricuspid regurgitation (especially atrial A-STR) shows a higher prevalence in older women. In patients with atrial fibrillation, the incidence of tricuspid regurgitation is 4–5 times higher than in the general population. Residual or new tricuspid regurgitation after left-sided valve surgery is reported in about 15–30%.
As the prevalence of atrial fibrillation and heart failure increases worldwide, the prevalence of tricuspid regurgitation is also increasing. Before the advent of transcatheter tricuspid procedures, many patients with tricuspid regurgitation could not undergo surgical treatment because of advanced age and high risk and received only medical therapy.
The key to the pathogenesis of secondary (functional) tricuspid regurgitation is annular dilation and leaflet tethering due to right ventricular pressure and volume overload. When pulmonary venous pressure rises due to left heart failure or mitral valve disease, pulmonary hypertension develops secondarily, imposing pressure overload on the right ventricle. As the right ventricle dilates, the tricuspid annulus also dilates, and geometric abnormalities of the papillary muscles and chordae pull the leaflets downward (tethering), making leaflet coaptation incomplete and producing regurgitation.
In atrial secondary tricuspid regurgitation (A-STR), right ventricular function is normal, and the main mechanism is persistent annular dilation due to chronic atrial enlargement. In this case, annular dilation itself rather than tethering is the cause of regurgitation, and abnormally increased right atrial pressure and atrial muscle fibrosis due to atrial fibrillation promote annular dilation.
Once regurgitation develops, right ventricular dilation due to volume overload worsens, which in turn aggravates annular dilation and tethering, forming a vicious cycle. Long-standing severe tricuspid regurgitation leads to right ventricular dysfunction, systemic venous congestion, congestive hepatopathy, and decreased renal function, and because right ventricular function is difficult to recover once damaged, early treatment is important.
Symptoms of nonrheumatic tricuspid regurgitation appear mainly as symptoms of right heart failure. Mild regurgitation is mostly asymptomatic, but symptoms develop as it progresses to moderate or greater. Lower extremity edema is the most common symptom, initially appearing later in the day and gradually developing into persistent edema. Abdominal bloating and ascites are due to increased portal pressure and hepatic congestion and are accompanied by resulting anorexia, nausea, and weight loss.
As hepatic congestion worsens, mild jaundice may appear due to elevated liver enzymes and increased bilirubin. Chronic hepatic congestion can progress to congestive hepatopathy and in some cases cause cardiac cirrhosis. Decreased urine output due to reduced renal function, fatigue, and reduced exercise tolerance are also common complaints. When tricuspid stenosis is present, dizziness and fatigue due to reduced cardiac output are prominent, and a markedly increased a wave appears in the jugular venous waveform.
The characteristic physical examination finding of tricuspid regurgitation is elevated jugular venous pressure (JVP) together with a markedly increased systolic v wave in the jugular venous waveform. In tricuspid regurgitation, a characteristic pattern is observed in which the jugular venous pulsation rises during systole (systolic jugular venous regurgitant pulsation). On auscultation, a holosystolic murmur is heard at the left lower sternal border, and the Carvallo sign, in which the murmur increases with inspiration, is characteristic.
Due to right ventricular dilation, the apical impulse shifts toward the left sternal border, and a right ventricular gallop (S3 or S4) may be heard. Pulsatile hepatomegaly is a characteristic finding of tricuspid regurgitation, with systolic hepatic pulsation felt on right subcostal palpation. Ascites and lower extremity edema reflect the degree of right heart failure, and weight gain and taut skin are observed. Peripheral cyanosis and cold hands and feet suggest reduced cardiac output.
Screening for tricuspid regurgitation is mainly carried out based on clinical risk factors and symptoms. Regular echocardiography is recommended in patients with high-risk conditions such as atrial fibrillation, mitral valve disease, pulmonary hypertension, and congenital heart disease. In particular, echocardiography to assess tricuspid size and function is essential before and after left-sided valve surgery.
In secondary tricuspid regurgitation, it is important to assess the tricuspid valve at the same time during follow-up testing of the underlying disease (left-sided valve disease, heart failure, etc.). In all patients reporting right heart failure symptoms (lower extremity edema, ascites, fatigue), it is appropriate to include tricuspid regurgitation in the differential diagnosis and perform echocardiography. The severity of tricuspid regurgitation and follow-up intervals are divided into mild (5 years), moderate (1–2 years), and severe (6–12 months).
Transthoracic echocardiography (TTE) is the basic test for the diagnosis and severity assessment of tricuspid regurgitation. 2D echocardiography confirms valve morphology (normal, leaflet tethering, valve deformity, etc.) and annular size (diameter >40 mm or >21 mm/m² BSA is the criterion for significant dilation), and Doppler evaluates the direction and severity of regurgitation. As severity indicators, effective regurgitant orifice area (EROA ≥40 mm²), regurgitant volume (≥45 mL/beat), and vena contracta (≥7 mm) are used. Evaluation of right ventricular function (TAPSE, S' velocity, FAC) is also essential.
3D echocardiography is advantageous for accurate assessment of valve anatomy and annular size and is particularly important when planning transcatheter procedures. Transesophageal echocardiography (TEE) is essential for clarifying the valve mechanism, confirming endocarditic vegetations, and guiding transcatheter procedures. Cardiac CT is used to evaluate valve anatomy and access routes before transcatheter tricuspid procedures. Cardiac MRI has strengths in quantifying regurgitant volume and accurately assessing right ventricular function. Blood tests (BNP/NT-proBNP, liver function tests, renal function tests) are useful for assessing the severity of heart failure and organ damage.
In secondary tricuspid regurgitation, treatment of the underlying disease comes first. Regurgitation may improve with guideline-directed medical therapy (GDMT) for heart failure, rate and rhythm control of atrial fibrillation, and treatment of pulmonary hypertension. Diuretics (loop diuretics, aldosterone antagonists) are used to relieve right heart failure symptoms (edema, ascites) but do not treat the regurgitation itself.
Surgical tricuspid valve repair is the most definitive treatment, with annular correction by annuloplasty ring implantation as the basis. Prophylactic tricuspid repair is recommended at the time of left-sided valve surgery when tricuspid regurgitation is present or the annular diameter is ≥40 mm. If the valve itself is severely damaged, tricuspid valve replacement is performed. In tricuspid replacement, tissue valves are preferred whenever possible because mechanical valves carry a high risk of thrombosis.
Transcatheter tricuspid procedures are a new treatment option for patients at high surgical risk. TriClip (transcatheter tricuspid edge-to-edge repair) and EVOQUE (transcatheter tricuspid valve replacement), approved by the FDA in 2024, have demonstrated safety and improved quality of life in clinical trials. In the TRILUMINATE Pivotal study, TriClip showed a significant reduction in tricuspid regurgitation grade and improvement in quality of life at 1-year follow-up.
Severe tricuspid regurgitation is a prognostic factor that independently increases mortality. In cohort studies, 1-year mortality in patients with severe tricuspid regurgitation is reported to be about 36%, and 5-year mortality reaches about 60%. Prognosis is even worse when accompanied by organ damage such as right ventricular dysfunction, decreased renal function, and hepatic congestion. In particular, reduced right ventricular systolic function (TAPSE <17 mm) is a strong poor prognostic factor.
After surgical tricuspid repair or replacement, recovery of right ventricular function and symptom improvement are expected, but if right ventricular function was already severely reduced before surgery, postoperative recovery may be incomplete. In short-term follow-up after transcatheter procedures (TriClip, EVOQUE), reduced regurgitation and improved quality of life have been confirmed, and resulting right ventricular reverse remodeling and improved long-term prognosis are expected. Early treatment is key to preserving right ventricular function and improving prognosis.
The most important prevention strategy for secondary tricuspid regurgitation is early treatment and prevention of the underlying disease. Atrial fibrillation is the most important modifiable risk factor, and suppressing the onset and persistence of atrial fibrillation can prevent the development and progression of tricuspid regurgitation. Maintenance of sinus rhythm through antiarrhythmic therapy, catheter ablation, and similar measures is recommended.
In patients with mitral valve disease, a preventive approach of performing tricuspid repair concomitantly during left-sided valve surgery is recommended. Current ACC/AHA and ESC guidelines recommend concomitant repair during mitral valve surgery when there is annular dilation (≥40 mm) or mild or greater tricuspid regurgitation. Early diagnosis and treatment of pulmonary hypertension also contribute to protecting the right ventricle and preventing tricuspid regurgitation.
Prevention of primary tricuspid regurgitation depends on the cause. Prevention of infective endocarditis (appropriate dental and skin hygiene, antibiotic prophylaxis in high-risk groups) is important. Linking patients who inject drugs to substance use treatment programs to prevent infective tricuspid endocarditis is also a clinically important prevention strategy.
Dreyfus GD, Corbi PJ, Chan KM, Bahrami T. Secondary tricuspid regurgitation or dilatation: which should be the criterion for surgical repair? Annals of Thoracic Surgery. 2005;79(1):127-132. DOI: 10.1016/j.athoracsur.2004.06.057. PMID: 15620928.
Lancellotti P, Tribouilloy C, Hagendorff A, et al. European Association of Echocardiography recommendations for the assessment of valvular regurgitation. European Journal of Echocardiography. 2010;11(4):307-332. DOI: 10.1093/ejechocard/jeq041. PMID: 20375260.
Topilsky Y, Maltais S, Medina Inojosa J, et al. Burden of Tricuspid Regurgitation in Patients Diagnosed in the Community Setting. JACC: Cardiovascular Imaging. 2019;12(3):433-442. DOI: 10.1016/j.jcmg.2018.06.014. PMID: 30121261.
Dreyfus J, Flagiello M, Bazire B, et al. Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes. European Heart Journal. 2020;41(45):4304-4317. DOI: 10.1093/eurheartj/ehaa643. PMID: 32945854.
Obadia JF, Messika-Zeitoun D, Leurent G, et al. (TRILUMINATE Pivotal Investigators). Transcatheter Repair for Patients with Tricuspid Regurgitation. New England Journal of Medicine. 2022;387(20):1843-1854. DOI: 10.1056/NEJMoa2200276. PMID: 36124685.
Dreyfus J, Bohbot Y, Coisne A, et al. Atrial secondary tricuspid regurgitation: pathophysiology, definition, diagnosis, and treatment. European Heart Journal. 2024;45(11):895-910. DOI: 10.1093/eurheartj/ehad831. PMID: 38291873.
Taramasso M, Hahn RT, Alessandrini H, et al. The International Multicenter TriValve Registry: Which Patients Are Undergoing Transcatheter Tricuspid Repair? JACC: Cardiovascular Interventions. 2017;10(19):1982-1990. DOI: 10.1016/j.jcin.2017.08.011. PMID: 28935076.
Vahanian A, Beyersdorf F, Praz F, et al. (ESC/EACTS Scientific Document Group). 2021 ESC/EACTS Guidelines for the management of valvular heart disease. European Heart Journal. 2022;43(7):561-632. DOI: 10.1093/eurheartj/ehab395. PMID: 34453165.
Nkomo VT, Gardin JM, Skelton TN, et al. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005-1011. DOI: 10.1016/S0140-6736(06)69208-8. PMID: 16980116.
Bartko PE, Arfsten H, Heitzinger G, et al. A Unifying Concept for the Quantitative Assessment of Secondary Mitral and Tricuspid Regurgitation. JACC: Cardiovascular Imaging. 2019;12(4):622-632. DOI: 10.1016/j.jcmg.2018.07.014. PMID: 30257860.